医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CartiHeal Granted Four Patents Covering Agili-C™ Cartilage Regeneration Technology

2014年09月03日 PM08:00
このエントリーをはてなブックマークに追加


 

KFAR SABA, Israel

CartiHeal (2009) Ltd., a privately held medical device company headquartered in Kfar Saba, Israel, announces the issuance of four patents — three in the U.S. and one in Japan — for its proprietary cell-free, off-the-shelf cartilage regeneration technology for patients with injuries to the articular surface of joints.

The three U.S. patents nos. 8,808,725, 8,790,681 and 8,802,115, and the Japanese patent 5536793, describe the use of modified coral scaffolds for the treatment of cartilage and bone defects. These patents cover a wide range of claims including treatment of cartilage and osteochondral defects, osteoarthritis and a variety of joint disorders. The patents relate to the Agili-C™ implant, a bi-phasic, coralline-hyaluronate composite scaffold which has undergone chemical, physical and biological modifications. The implant demonstrated clinical safety and effectiveness in a series of clinical trials, by enhancing regeneration of true hyaline cartilage and subchondral bone.

“These four patents strengthen CartiHeal’s IP portfolio, and position the company at the forefront of innovative technologies in the field of cartilage regeneration,” reports Nir Altschuler, founder and CEO of CartiHeal. “Cartilage regeneration represents one of medicine’s most challenging unmet needs. We are proud to say that CartiHeal and its breakthrough technology are able to meet this challenge.”

About CartiHeal

CartiHeal (2009) Ltd., a privately held medical device company headquartered in Israel, is a pioneer in the field of regenerative medicine. CartiHeal’s CE-marked Agili-C™ implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. Agili-C™ represents a significant medical breakthrough and was voted one of the top 10 most exciting Israeli medical-device and pharmaceutical developments to watch for in 2014.

For more information about the company please visit: www.cartiheal.com

CONTACT

CartiHeal
Caty Pearl, +972-54-8081020
Marketing Manager
catyp@pearlcom.co.il

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高